A mixed after-hours session saw AI hardware and nuclear energy names surge while enterprise software, biotech, and airline stocks slid

Key Highlights

  • Three Sharp Gainers: SMCI, OKLO, and XE all posted double-digit percentage gains on margin guidance and federal nuclear program news.
  • Three Notable Decliners: PEGA, CLDX, and ALK all fell on earnings misses, a clinical trial failure, and weak forward guidance respectively.
  • Diverse Catalysts Across Sectors: The moves spanned AI hardware, advanced nuclear energy, enterprise software, biotechnology, and airlines within a single session.

A busy after-hours trading session produced sharp moves across six stocks spanning AI hardware, advanced nuclear energy, enterprise software, biotechnology, and airlines, illustrating how earnings updates, clinical trial results, and sector-specific policy news can all converge to move markets on the same day. Three names surged on positive catalysts, while three others slid on disappointing results or setbacks.

The Winners: AI Hardware and Nuclear Energy Catalysts

Super Micro Computer (NASDAQ: SMCI) led the gainers, surging as much as 20% intraday and extending gains after hours, following a preliminary fiscal Q4 2026 update showing gross margins of 15% to 17%, nearly double prior guidance, alongside record new orders above $60 billion. The update lifted server peers Dell Technologies and Hewlett Packard Enterprise in sympathy during the regular session.

Nuclear energy developers Oklo (NYSE: OKLO) and X-Energy (NASDAQ: XE) also rallied, up 8% and 12% respectively, after reports that both companies are joining a $200 million federal program alongside Microsoft and NVIDIA to accelerate nuclear reactor development for AI data centers, a theme directly tied to the broader push to secure reliable power for the AI infrastructure buildout.

The Decliners: Software, Biotech, and Airline Disappointments

On the other side of the ledger, Pegasystems (NASDAQ: PEGA) slid more than 13% after hours following a second-quarter earnings and revenue miss that extended a difficult 2026 for the enterprise AI software provider, which had already lost roughly 46% of its value this year amid an ongoing transition to Pega Cloud subscription revenue.

Celldex Therapeutics (NASDAQ: CLDX) fell 8% after its Phase 2 study of barzolvolimab in prurigo nodularis failed to meet its primary and secondary endpoints, despite the drug demonstrating profound mast cell depletion. Alaska Air Group (NYSE: ALK) slid 4% after issuing third-quarter earnings guidance well below consensus, even as its second-quarter results came in slightly ahead of expectations.

A Session Defined by Diverging Catalysts

Taken together, this session illustrates how disparate corporate and policy developments, ranging from a hardware margin surprise to a federal energy initiative to a clinical trial readout, can produce sharply divergent outcomes across sectors on the same trading day, underscoring the value of tracking company-specific catalysts alongside broader market and sector trends.

Disclaimer: This article is for informational purposes only and does not constitute financial, investment, or trading advice. Readers should conduct their own research or consult a licensed financial advisor before making investment decisions. Past performance is not indicative of future results.